Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OCTOVA
- 27 Sep 2018 Planned number of patients changed from 132 to 138.
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.